Lung cancer is the leading cause of cancer death in the United States. Oncologists need to be aware of new treatment options and recommendations so they can implement the best treatment plans and thus improve outcomes for their patients with lung cancer.

Lung cancer is the leading cause of cancer death in the United States. Oncologists need to be aware of new treatment options and recommendations so they can implement the best treatment plans and thus improve outcomes for their patients with lung cancer.

Join Leora Horn, MD, MSc, FRCPC and Christine Lovly, MD, PhD as they present their multidisciplinary expertise on a range of cases pertaining to biomarker driven advanced disease lung cancer.

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Lung Cancer Screening provide recommendations for selecting individuals for lung cancer screening, and for evaluation and follow-up of nodules found during screening, and are intended to assist with clinical and shared decisi

Lung cancer is the leading cause of cancer death in the United States. Oncologists need to be aware of new treatment options and recommendations so they can implement the best treatment plans and thus improve outcomes for their patients with lung cancer.

Lung cancer is the leading cause of cancer death in the United States. Oncologists need to be aware of new treatment options and recommendations so they can implement the best treatment plans and thus improve outcomes for their patients with lung cancer.

Lung cancer is the leading cause of cancer death in the United States. Oncologists need to be aware of new treatment options and recommendations so they can implement the best treatment plans and thus improve outcomes for their patients with lung cancer.

Stereotactic body radiotherapy (SBRT) has become the standard of care for patients with medically inoperable early-stage non-small cell lung cancer. A paucity of published data exists regarding the safety of SBRT use in patients with prior pneumonectomy.

Join Leora Horn, MD, MSc, FRCPC and Christine Lovly, MD, PhD as they present their multidisciplinary expertise on a range of cases pertaining to biomarker driven advanced disease lung cancer.

Lung cancer is the leading cause of cancer death in the United States. Oncologists need to be aware of new treatment options and recommendations so they can implement the best treatment plans and thus improve outcomes for their patients with lung cancer.